Sotalol: a new agent for the treatment of ventricular arrhythmias.
Sotalol was developed as a nonselective beta-blocker in the 1960s for the treatment of hypertension and later for cardiac risk management after myocardial infarction. Extensive research has since well described class III type electrophysiologic effects on the repolarization of myocardial fibers. Sotalol prolongs and homogenizes ventricular refractoriness, resulting in good antifibrillatory/antitachycardia protection. The unique combination of beta-blockade and antiarrhythmic effects probably will promote sotalol's use in postmyocardial infarction patients with ventricular tachycardia and sudden death. This article summarizes the pharmacologic and cardiovascular effects of this new drug, outlining its clinical use.[1]References
- Sotalol: a new agent for the treatment of ventricular arrhythmias. Samoil, D., Grubb, B.P., Temesy-Armos, P.N. Am. J. Med. Sci. (1994) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg